From Pricing To Patents: Hearing Signals A Potential New Focus
Executive Summary
Sen. Cornyn recommended the Judiciary Committee initiate an inquiry into drug patents after a back-and-forth with AbbVie CEO Gonzalez over the Humira patent estate at the drug pricing hearing.
You may also be interested in...
Battle Over Patents And Drug Pricing Engulfs FDA And USPTO
President Biden and Congress are pressuring the agencies to change patent policies so brand manufacturers cannot delay generic and biosimilar competition to keep monopoly prices. Timeline shows how they have responded to these demands.
FDA, USPTO In Middle Of Congressional Tug-Of-War Over Patents And Drug Pricing
Senators Hassan and Cassidy contend the lack of coordination between the two agencies may allow patent thickets to grow. Meanwhile, Sen. Tillis is pushing the agency to refute data alleging patents are to blame for high drug prices.
Congress Puts Focus Back On Drug Pricing With AbbVie Subpoena
House Oversight Committee Chair says AbbVie has failed to comply with requests for documents in committee's investigation of the drug pricing of 12 pharma companies.